earticle

영어

BACKGROUND: The tiger milk mushroom has been extolled for centuries due to its medicinal properties. In Malaysia, the major species Lignosus rhinocerus is recorded by ethnomycological writings to have therapeutic values. Prior to its successful cultivation in 2009, there were no records of scientific studies due to unavailability of sufficient samples. A patented solid state fermentation method successfully cultivated TM02®; followed by the development of ACE Technology to produce its extract xLr® are the first of its kind in the world and can produce a consistent supply of both the TM02® sclerotia and its extract, xLr®. Thorough study which encompassed chronic1, subacute2, and acute toxicity, genotoxicity, antifertility, and teratogenic effects was conducted to enable mass commercialization. Rigorous scientific investigations have been done to validate its traditional use and to investigate its biochemical and biopharmacological properties. RESULTS: TM02® and xLr® contain Rhinoprolycan3 fraction as its active component which could play possible role in rendering significant therapeutic properties such as antiinflammatory4, immuno-modulatory3, anti-proliferative5, anti-oxidative6, neurite outgrowth stimulation and anti-AGE7. It is proven to be effective in supporting the lung and respiratory health, immune health, maintenance of joint health (caused by inflammation), improving vitality and stamina and improving the quality of life for cancer patients. The revelation of the genome, transcriptome, proteome of L. rhinocerus has provided valuable insights into the biomolecule discovery and provided the foundation for future research and exploitation in pharmacological and functional food applications. The most recent pandemic accelerated the visibility of tiger milk mushroom for use to overcome chronic cough and severity of the infection8. CONCLUSION: It is a listed traditional medicine active ingredient list under the Malaysian National Pharmaceutical Control Bureau and the TM02® cultivar has also been filed under the New Plant Variety Protection (NPVP) of Malaysia. This is the first medicinal mushroom species that has experienced the bench to bedside framework – having had successfully completed 4 clinical trials to date with one more ongoing.